AI Summary
Thinking
Thinking
We reviewed 11 live results for xembify connexions and narrowed them down to the 3 options that look most worth comparing first.
The options are Xembify Connexions™, Xembify and Xembify.
Source: Xembify
Description
Xembify Connexions is a dedicated patient support and financial assistance program. It offers a zero copay program for eligible commercially insured patients (up to $10,000 annually), specialized Nurse Educators (IgNE) for self-administration training, and administrative assistance for insurance benefits verification and prior authorization.
Best for
commercially insured patients, new therapy onboarding, financial assistance seekers and insurance navigation help
Rate this product
Source: Grifols
Description
Xembify is a 20% liquid SCIG indicated for Primary Humoral Immunodeficiency (PI) in patients 2 years and older. It is formulated as a highly purified IgG solution (at least 98% IgG).
Best for
PI patients, high purity requirements, pediatric patients and SCIG therapy
Rate this product
Source: Grifols
Description
Xembify is a 20% subcutaneous human normal immunoglobulin (SCIG) solution developed by Grifols. It is indicated for the treatment of primary immunodeficiencies (PIDD) and select secondary immunodeficiencies (SID), specifically hypogammaglobulinemia and recurrent bacterial infections in patients with chronic lymphocytic leukemia where preventive antibiotics have been ineffective. This immunotherapy is administered via subcutaneous injection, with common injection sites including the abdomen, thigh, upper arm, and lateral hip. It is available in various vial sizes containing 1 g (5 mL), 2 g (10 mL), 4 g (20 mL), and 10 g (50 mL) of immunoglobulin.
Best for
Patients with primary immunodeficiencies, Patients with select secondary immunodeficiencies, Treatment of hypogammaglobulinemia, Chronic lymphocytic leukemia patients with recurrent bacterial infections and Subcutaneous immunoglobulin therapy
Rate this product
| Compare | #1Xembify Connexions™ | #2Xembify | #3Xembify |
|---|---|---|---|
| Source | Xembify | Grifols | Grifols |
| Description | Xembify Connexions is a dedicated patient support and financial assistance program. It offers a zero copay program for eligible commercially insured patients (up to $10,000 annually), specialized Nurse Educators (IgNE) for self-administration training, and administrative assistance for insurance benefits verification and prior authorization. | Xembify is a 20% liquid SCIG indicated for Primary Humoral Immunodeficiency (PI) in patients 2 years and older. It is formulated as a highly purified IgG solution (at least 98% IgG). | Xembify is a 20% subcutaneous human normal immunoglobulin (SCIG) solution developed by Grifols. It is indicated for the treatment of primary immunodeficiencies (PIDD) and select secondary immunodeficiencies (SID), specifically hypogammaglobulinemia and recurrent bacterial infections in patients with chronic lymphocytic leukemia where preventive antibiotics have been ineffective. This immunotherapy is administered via subcutaneous injection, with common injection sites including the abdomen, thigh, upper arm, and lateral hip. It is available in various vial sizes containing 1 g (5 mL), 2 g (10 mL), 4 g (20 mL), and 10 g (50 mL) of immunoglobulin. |
| Best for | commercially insured patients, new therapy onboarding, financial assistance seekers and insurance navigation help | PI patients, high purity requirements, pediatric patients and SCIG therapy | Patients with primary immunodeficiencies, Patients with select secondary immunodeficiencies, Treatment of hypogammaglobulinemia, Chronic lymphocytic leukemia patients with recurrent bacterial infections and Subcutaneous immunoglobulin therapy |
| Action | Xembify | Grifols | Grifols |
| Rate this product |
"Xembify Connexions™ from Xembify."
TopFind picked this because This program significantly reduces the financial and educational barriers to treatment with copay assistance and hands-on clinical training.
Note: TopFind AI compiles product and service information for general comparison purposes only.